Oral Immunization With a M Cell-Targeting Recombinant L. Lactis Vaccine LL-plSAM-FVpE Stimulate Protective Immunity Against H. Pylori in Mice

被引:13
作者
Guo, Le [1 ,2 ,3 ]
Zhang, Furui [1 ]
Wang, Shue [1 ]
Li, Runle [4 ]
Zhang, Lele [1 ]
Zhang, Zhen [5 ]
Yin, Runting [6 ]
Liu, Hongpeng [1 ]
Liu, Kunmei [1 ,7 ]
机构
[1] Ningxia Med Univ, Sch Clin Med, Dept Med Lab, Yinchuan, Peoples R China
[2] Ningxia Med Univ, Ningxia Key Lab Clin & Pathogen Microbiol, Gen Hosp, Yinchuan, Peoples R China
[3] Wenzhou Med Univ, Key Lab Radiat Oncol Taizhou, Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China
[4] Qinghai Univ, Res Ctr High Altitude Med, Xining, Peoples R China
[5] Ningxia Med Univ, Canc Hosp, Gen Hosp, Yinchuan, Peoples R China
[6] Jiangsu Univ, Sch Pharm, Zhenjiang, Peoples R China
[7] Ningxia Med Univ, Ningxia Key Lab Cerebrocranial Dis, Yinchuan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
H; pylori; virulence factor; recombinant L; lactis vaccine; M cell-targeting; surface display system; NEUTROPHIL-ACTIVATING PROTEIN; HELICOBACTER-PYLORI; LACTOCOCCUS-LACTIS; INFECTION; IMMUNOGENICITY; EFFICACY; DELIVERY; ABSENCE; UREASE; SAFETY;
D O I
10.3389/fimmu.2022.918160
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There are many virulence factors of H. pylori that contribute in diverse ways to gastric disease. Therefore, designing multivalent epitope vaccines against many key virulence factors virulence factors of H. pylori is a promising strategy to control H. pylori infection. In previous studies, we constructed a multivalent epitope vaccine FVpE against four key virulence factors of H. pylori (Urease, CagA, VacA, and NAP), and oral immunization with the FVpE vaccine plus a polysaccharide adjuvant (PA) containing lycium barbarum polysaccharide and chitosan could provide protection against H. pylori infection in the Mongolian gerbil model. Oral vaccines have many advantages over injected vaccines, such as improved safety and compliance, and easier manufacturing and administration. However, the harsh gastrointestinal (GI) environment, such as gastric acid and proteolytic enzymes, limits the development of oral vaccines to some extent. Oral vaccines need a gastrointestinal delivery system with high safety, low price and promoting vaccine antigen to stimulate immune response in the gastrointestinal mucosa. Lactic acid bacteria are gastrointestinal probiotics that have unique advantages as a delivery system for oral vaccines. In this study, a M cell-targeting surface display system for L. lactis named plSAM was designed to help vaccine antigens to stimulate effective immune responses in the gastrointestinal tract, and a M cell-targeting recombinant L. lactis vaccine LL-plSAM-FVpE was constructed by using the surface display system plSAM. recombinant L. lactis vaccine LL-plSAM-FVpE could secretively express the SAM-FVpE protein and display it on the bacterial surface. Moreover, experimental results confirmed that LL-plSAM-FVpE had an enhanced M cell-targeting property. In addition, LL-plSAM-FVpE had excellent M cell-targeting property to promote the phagocytosis and transport of the antigen SAM-FVpE by gastrointestinal M cells. More importantly, oral immunization of LL-plSAM-FVpE or SAM-FVpE plus PA can stimulate IgG and sIgA antibodies and CD4(+) T cell immune responses against four virulence factors of H. pylori (Urease, CagA, VacA, and NAP), thus providing protective immunity against H. pylori infection in mice. The M cell-targeting recombinant L. lactis vaccine against various key H. pylori virulence factors could be a promising vaccine candidate for controlling H. pylori infection.
引用
收藏
页数:13
相关论文
共 46 条
[1]   The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses [J].
Amedei, A ;
Cappon, A ;
Codolo, G ;
Cabrelle, A ;
Polenghi, A ;
Benagiano, M ;
Tasca, E ;
Azzurri, A ;
D'Elios, MM ;
Del Prete, G ;
de Bernard, M .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (04) :1092-1101
[2]   Challenges in mucosal vaccines for the control of infectious diseases [J].
Azegami, Tatsuhiko ;
Yuki, Yoshikazu ;
Kiyono, Hiroshi .
INTERNATIONAL IMMUNOLOGY, 2014, 26 (09) :517-528
[3]   Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes [J].
Cano-Garrido, Olivia ;
Seras-Franzoso, Joaquin ;
Garcia-Fruitos, Elena .
MICROBIAL CELL FACTORIES, 2015, 14
[4]   The Helicobacter pylori Cag Type IV Secretion System [J].
Cover, Timothy L. ;
Lacy, D. Borden ;
Ohi, Melanie D. .
TRENDS IN MICROBIOLOGY, 2020, 28 (08) :682-695
[5]   Helicobacter pylori VacA, a paradigm for toxin multifunctionality [J].
Cover, TL ;
Blanke, SR .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (04) :320-332
[6]   The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent [J].
D'Elios, Mario Milco ;
Amedei, Amedeo ;
Cappon, Andrea ;
Del Prete, Gianfranco ;
de Bernard, Marina .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2007, 50 (02) :157-164
[7]   Regular review -: Treatment of Helicobacter pylori infection [J].
de Boer, WA ;
Tytgat, GNJ .
BRITISH MEDICAL JOURNAL, 2000, 320 (7226) :31-34
[8]   Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses [J].
Ermak, TH ;
Giannasca, PJ ;
Nichols, R ;
Myers, GA ;
Nedrud, J ;
Weltzin, R ;
Lee, CK ;
Kleanthous, H ;
Monath, TP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2277-2288
[9]   Antigenicity and Immunogenicity of Rotavirus VP6 Protein Expressed on the Surface of Lactococcus lactis [J].
Esteban, L. E. ;
Temprana, C. F. ;
Argueelles, M. H. ;
Glikmann, G. ;
Castello, A. A. .
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[10]   Regulation of gastric carcinogenesis by helicobacter pylori virulence factors [J].
Franco, Aime T. ;
Johnston, Elizabeth ;
Krishna, Uma ;
Yamaoka, Yoshio ;
Israel, Dawn A. ;
Nagy, Toni A. ;
Wroblewski, Lydia E. ;
Piazuelo, Maria Blanca ;
Correa, Pelayo ;
Peek, Richard M., Jr. .
CANCER RESEARCH, 2008, 68 (02) :379-387